Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of ibrutinib in combination with rituximab-CHOP in Epstein-Barr virus-positive diffuse large B-cell lymphoma
KCT0002919Phase 2Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib in Epstein-Barr virus-positive diffuse large B-cell lymphoma, sponsored by Janssen Pharmaceutical. Started Oct 2016; status: recruiting.
02
Drugs
ibrutinib
03
Conditions
Epstein-Barr virus-positive diffuse large B-cell lymphoma
Beyond the preview
Go deeper on KCT0002919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0002919.